Baidu
map

ALZHEIMERS DEMENT:科学家预测阿尔兹海默增长趋势

2017-12-10 海北 MedSci原创

随着全球老龄化的进程,阿尔兹海默病成了社会关注的重点。近日,来自加州大学的研究人员预测了临床前和临床阿尔茨海默病(AD)的患病率,并评估美国一级和二级预防的潜在影响。

随着全球老龄化的进程,阿尔兹海默病成了社会关注的重点。近日,来自加州大学的研究人员预测了临床前和临床阿尔茨海默病(AD)的患病率,并评估美国一级和二级预防的潜在影响。

研究人员使用了一个多国家模式,并结合了临床前AD生物标志物与美国人口预测情况。

研究人员预测,到2017年,美国大约会有608万人后患有临床确诊的阿尔兹海默或是因为阿尔兹海默引起轻度认知障碍。而到2060年,这个数字会增长到1500万。而在2017年,4670万美国人患有临床前阿尔兹海默症状(淀粉样变性,神经退化或两者兼有)。但是许多人在他们的一生中都可能不会发展成临床疾病。研究人员预测,一级和二级预防对未来疾病负担有不同的影响。

鉴于大量人群具有患临床前阿尔兹海默的风险,因此该研究结果强调了对可能发展为临床疾病的人群的二级预防需求,以及无临床前疾病的人群的一级预防需求。


原始出处:

Ron Brookmeyer et al. Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States. Alzheimer's & Dementia, 2017; DOI: 10.1016/j.jalz.2017.10.009


本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779766, encodeId=3c9e1e7976610, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Dec 21 21:44:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878244, encodeId=f8fa18e824414, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 28 17:44:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338465, encodeId=12251338465a8, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Tue Dec 12 05:44:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402742, encodeId=32eb1402e4202, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Tue Dec 12 05:44:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268605, encodeId=dc07268605de, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:22:29 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779766, encodeId=3c9e1e7976610, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Dec 21 21:44:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878244, encodeId=f8fa18e824414, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 28 17:44:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338465, encodeId=12251338465a8, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Tue Dec 12 05:44:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402742, encodeId=32eb1402e4202, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Tue Dec 12 05:44:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268605, encodeId=dc07268605de, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:22:29 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2018-07-28 anminleiryan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779766, encodeId=3c9e1e7976610, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Dec 21 21:44:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878244, encodeId=f8fa18e824414, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 28 17:44:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338465, encodeId=12251338465a8, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Tue Dec 12 05:44:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402742, encodeId=32eb1402e4202, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Tue Dec 12 05:44:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268605, encodeId=dc07268605de, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:22:29 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779766, encodeId=3c9e1e7976610, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Dec 21 21:44:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878244, encodeId=f8fa18e824414, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 28 17:44:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338465, encodeId=12251338465a8, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Tue Dec 12 05:44:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402742, encodeId=32eb1402e4202, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Tue Dec 12 05:44:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268605, encodeId=dc07268605de, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:22:29 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1779766, encodeId=3c9e1e7976610, content=<a href='/topic/show?id=51b4238909' target=_blank style='color:#2F92EE;'>#alzheimers#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2389, encryptionId=51b4238909, topicName=alzheimers)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Dec 21 21:44:00 CST 2017, time=2017-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878244, encodeId=f8fa18e824414, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 28 17:44:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338465, encodeId=12251338465a8, content=<a href='/topic/show?id=767711566a9' target=_blank style='color:#2F92EE;'>#MERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11566, encryptionId=767711566a9, topicName=MERS)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/71tKRib0PibveVjnEa7tPLMaCzoKicFlKSEOzRTGf4wNvDV54kJyNx1ott1D5Xp5gRu7IwUia77oN0YFdffvQMu6Ug/132, createdBy=9e302500146, createdName=ms49895894946433513521, createdTime=Tue Dec 12 05:44:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402742, encodeId=32eb1402e4202, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Tue Dec 12 05:44:00 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268605, encodeId=dc07268605de, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 11 13:22:29 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-11 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

Brain:线粒体自噬是治疗阿尔兹海默的潜在疗法

线粒体功能障碍和突触损伤是阿尔茨海默症病人脑部出现的早期病理特征。伴随着阿尔茨海默的记忆障碍是脑病变的表现,如淀粉样蛋白-β肽的积累和线粒体的损伤。

Autophagy:华人科学家发现自噬介导淀粉样蛋白降解机制

阿尔兹海默病(AD)是以脑淀粉样斑块沉积为特征的非常常见的神经退行性疾病。已有的报导显示,自噬相关的含PIK3C3的磷脂酰肌醇3-激酶(PtdIns3K)复合物能够帮助APP的代谢以及淀粉样蛋白(Aβ)的体内平衡。但是至今为止,人们对其机制还不太了解。

AM J RESP CRIT CARE:睡眠呼吸暂停和阿尔兹海默相关

已有的研究表明,阻塞性睡眠呼吸暂停(OSA)可能是发展为轻度认知功能障碍和阿尔茨海默病的风险因素。但是至今为止,睡眠呼吸暂停如何影响阿尔茨海默病的纵向风险还不太清楚。

Mol Psychiatry:阿尔兹海默症“会转移”!竟是一种全身疾病!

长期以来,我们认为阿尔兹海默症是一个脑疾病,科学家也针对这种情况进行了各种治疗。但是近来我们发现,这些治疗手段,效果缺缺。就在昨日《Molecular Psychiatry》发表了一篇文章:阿尔兹海默症可能和癌症一样,是会转移的!并不单单是脑部疾病,更可能是全身性疾病!

Nature:靶向线粒体治疗阿尔兹海默

阿尔茨海默病是一种以淀粉样蛋白-β肽聚集为特征的常见且具有破坏性的疾病。然而,至今为止,我们对阿尔茨海默病的潜在分子机制或如何治疗这类患者还知之甚少。 来自洛桑联邦理工学院的研究人员提供了生物信息学和实验证据,表明线粒体应激反应信号存在于涉及人类,小鼠和秀丽隐杆线虫的淀粉样蛋白-β蛋白毒性的疾病中。这些疾病还涉及线粒体未折叠蛋白反应和线粒体自噬过程。 研究人员使用具有淀粉样蛋白-β毒性的蠕虫模

JACS:抑制阿尔茨海默症发展分子机制被发现!

众所周知,饮用绿茶对大脑具有很大的益处。绿茶提取物的抗氧化和解毒特性有助于抵抗阿尔茨海默病等重大疾病。然而,科学家至今没有完全了解绿茶发挥作用的分子机制,以及如何利用它们来寻找更好的治疗方法。

Baidu
map
Baidu
map
Baidu
map